Mubritinib

In today's article we are going to explore Mubritinib, a topic that has sparked the interest of many people over time. Mubritinib is a relevant aspect in today's society, since it affects different areas of daily life. Throughout this article we will examine various perspectives on Mubritinib, as well as its impact today. Furthermore, we will explore different approaches and opinions that have emerged around this topic, with the aim of providing a complete and enriching view of Mubritinib. Don't miss this interesting exploration of Mubritinib!

Mubritinib
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 1-(4-{4-ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC25H23F3N4O2
Molar mass468.480 g·mol−1
3D model (JSmol)
  • FC(F)(F)c1ccc(cc1)\C=C\c2nc(co2)COc3ccc(cc3)CCCCn4nncc4
  • InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+
  • Key:ZTFBIUXIQYRUNT-MDWZMJQESA-N

Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.

See also

References

  1. ^ McCormick F, Fabbro D (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. doi:10.1385/1-59259-962-1:001. ISBN 1-58829-384-X.
  2. ^ Mitscher LA, Lednicer D (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN 0-470-10750-2.
  3. ^ Lednicer D (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 978-0-470-19039-5.
  4. ^ Clinical trial number NCT00034281 for "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2" at ClinicalTrials.gov


Wikious
Boobota
Sagapedia